Medipal Holdings
Financials
Estimates*
JPY | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|---|---|---|
Revenues | 3.2t | 3.3t | 3.4t | 3.6t | 3.6t | 3.7t | 3.8t |
% growth | (1 %) | 2 % | 2 % | 6 % | 2 % | 2 % | 3 % |
EBITDA | 67.8b | 76.4b | 79.8b | 83.1b | 66.8b | 68.3b | 71.1b |
% EBITDA margin | 2 % | 2 % | 2 % | 2 % | 2 % | 2 % | 2 % |
Profit | 23.9b | 29.4b | 38.8b | 41.5b | 34.9b | 35.6b | 38.3b |
% profit margin | 1 % | 1 % | 1 % | 1 % | 1 % | 1 % | 1 % |
EV / revenue | 0.1x | 0.1x | 0.1x | 0.1x | 0.1x | 0.1x | 0.1x |
EV / EBITDA | 3.5x | 2.5x | 2.3x | 3.1x | 8.0x | 7.8x | 7.5x |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | N/A | IPO | |
N/A | N/A | IPO | |
$92.0m | Post IPO Equity | ||
Total Funding | - |
Recent News about Medipal Holdings
EditMedipal Holdings Corporation is a prominent player in the distribution of pharmaceuticals, medical devices, and health-related products in Japan. The company serves a diverse range of clients including hospitals, pharmacies, and healthcare institutions. Operating in the healthcare and pharmaceutical market, Medipal leverages an extensive supply chain network to ensure timely and efficient delivery of products. The business model focuses on wholesale distribution, earning revenue through the sale of medical and health-related products. Medipal also invests in logistics and information systems to enhance operational efficiency and customer satisfaction.
Keywords: pharmaceuticals, medical devices, health products, distribution, supply chain, logistics, healthcare, wholesale, Japan, efficiency.